EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Louis Talay iD, Jason Hom, Tamara Scott, Neera Ahuja

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70462 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Louis Talay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Arts and Social Sciences, University of Sydney SDN, Camperdown, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Tirzepatide, Weight Reduction Programs, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an Australian cohort using a tirzepatide‐supported medicated DWLS. Materials and Methods All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 ( n = 4309) were analysed. The study population was predominantly female (92.9%) and Caucasian (81.9%), with a mean age of 41.46 years and a mean baseline body mass index of 32.9 kg/m 2 . Primary endpoints were programme adherence at 6 and 12 months and mean percentage weight loss among adherent patients. Adherence required ≥5 medication orders and a weight entry at 173–193 days after programme initiation (6 months), or ≥10 orders and a weight entry 355–375 days post‐initiation (12 months). Full cohorts were analysed using last observation carried forward imputation.

Results

At 6 months, 31.7% met adherence criteria; mean weight loss among adherent patients was 16.9% (±8.6; 95% CI 16.6–17.2), with 98.0% achieving ≥5% weight reductions. At 12 months, 16.1% were adherent; mean weight loss was 22.7% (±7.2; 95% CI: 19.8–22.6) and 100% of patients reached the ≥5% milestone. Multivariable models identified 1‐month weight loss as the strongest predictor of 6‐ and 12‐month outcomes; sustained weekly weight tracking and health coach messaging were strongly associated with both retention and greater weight loss. Paradoxically, very frequent weight tracking in month one correlated with poorer outcomes and reduced retention. Side effects were common but mostly mild/moderate and did not correlate with weight loss or programme retention.

Conclusions

Tirzepatide plus multidisciplinary digital care yields large clinically meaningful weight loss among engaged users, but low adherence limits population‐level effectiveness. Early clinical response and sustained engagement are key drivers of adherence; however, interventions are needed to manage early weight‐loss expectations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideWeight Reduction ProgramsObesityAnti-Obesity AgentsPatient ComplianceHumansFemaleAdultAustraliaMaleRetrospective StudiesMiddle AgedWeight LossTreatment OutcomeDigital Health

Stichwörter der Autor:innen

antiobesity drugobesity careobservational studypatient reported outcomesreal‐world evidenceweight management

Substanzen

TirzepatideAnti-Obesity Agents

Autor:innen und Institutionen

  • Faculty of Arts and Social Sciences, University of Sydney SDN, Camperdown, Sydney, New South Wales, Australia.
  • Department of Medicine, Stanford University Medical Centre, Stanford, California, USA.

ORCID-Profile: Louis Talay

Zitieren

APA

Talay, L., Hom, J., Scott, T., & Ahuja, N. (2026). Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70462

Vancouver

Talay L, Hom J, Scott T, Ahuja N. Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70462

BibTeX
@article{Talay2026,
  author = {Talay, Louis and Hom, Jason and Scott, Tamara and Ahuja, Neera},
  title = {Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70462}
}
Kostenlos starten →